Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study.

Male Humans Female Hepatitis B virus / physiology Antirheumatic Agents / therapeutic use Biological Factors / therapeutic use Arthritis, Psoriatic / drug therapy Hepatitis B Surface Antigens Arthritis, Rheumatoid / drug therapy Rheumatic Diseases / drug therapy Immunoglobulin G / therapeutic use Virus Activation Antiviral Agents / therapeutic use

Biologic agents Hepatitis Inflammatory arthritis Viral reactivation

Journal

Rheumatology international

ISSN: 1437-160X

Titre abrégé: Rheumatol Int

Pays: Germany

ID NLM: 8206885

Informations de publication

Date de publication:
Mar 2023

Historique:

received: 01 06 2022

accepted: 01 07 2022

pubmed: 6 9 2022

medline: 3 3 2023

entrez: 5 9 2022

Statut: ppublish

Résumé

To evaluate of hepatitis serology and reactivation frequency in patients with rheumatic disease receiving biologic agents. Our study included patients with inflammatory rheumatic diseases from 23 centers, who were followed up with biological therapy. Demographic and clinical characteristics of the patients, duration of drug use and hepatitis serology and the state of viral reactivation were analyzed. A total of 4060 patients, 2095 being males, were included in our study. Of the patients, 2463 had Ankylosing Spondylitis (AS), 1154 had Rheumatoid Arthritis (RA), 325 had Psoriatic Arthritis (PsA), and 118 had other inflammatory rheumatic diseases. When the viral serology of the patients was evaluated, 79 patients (2%) who were identified as HBs Ag positive, 486 (12%) patients who were HBs Ag negative and anti-HBc IgG positive and 20 patients (0.5%) who were anti-HCV positive. When evaluated on a disease-by-disease basis, the rate of HBsAg was found to be 2.5% in RA, 2% in AS and 0.9% in PsA. Viral reactivation was detected in 13 patients while receiving biologic agents. HBs Ag was positive in nine patients with reactivation and negative in four patients. Anti-HBc IgG, however, was positive. Six of these patients had AS, four had RA, and three had PsA. The development of hepatitis reactivation in 11.4% of HBs Ag positive patients and 0.82% of anti-HBc IgG positive patients due to the use of biologic agents is an important problem for this group of patients. Antiviral prophylaxis is recommended to be started especially in patients who are HBs Ag positive and who are using biologic agents due to viral reactivation. Therefore, it is important to carry out hepatitis screenings before biologic agent treatment and to carefully evaluate the vaccination and prophylaxis requirements.

Identifiants

DOI: 10.1007/s00296-022-05169-2 PMID: 36063169

pubmed: 36063169

doi: 10.1007/s00296-022-05169-2

pii: 10.1007/s00296-022-05169-2

doi:

Substances chimiques

Antirheumatic Agents 0

Biological Factors 0

Hepatitis B Surface Antigens 0

Immunoglobulin G 0

Antiviral Agents 0

Types de publication

Multicenter Study Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

523-531

Informations de copyright

Références

Liang TJ, Block TM, McMahon BJ et al (2015) Present and future therapies of hepatitis B: from discovery to cure. Hepatology 62:1893–1908. https://doi.org/10.1002/hep.28025

doi: 10.1002/hep.28025 pubmed: 26239691

World Health Organization. Hepatitis B report (2017) Available from: http://www.who.int/mediacentre/factsheets/fs204/en/

Ozkan H (2018) Epidemiology of chronic hepatitis B in Turkey review. Euroasian J Hepatogastroenterol Jan–Jun 8:73–74. https://doi.org/10.5005/jp-journals-10018-1264

doi: 10.5005/jp-journals-10018-1264

Yılmaz N, Karadağ Ö, Kimyon G, Yazıcı A, Yılmaz S, Kalyoncu U, Kaşifoğlu T, Temiz H, Baysa B (2014) Prevalence of hepatitis B and C ınfections in rheumatoid arthritis and ankylosing spondylitis: a multicenter countrywide study. Eur J Rheumatol 1(2):51–54. https://doi.org/10.5152/eurjrheumatol.2014.018

doi: 10.5152/eurjrheumatol.2014.018 pubmed: 27708874 pmcid: 5042277

Evangelos C, Anna-Bettina H, Fani A, Parthenis C, George V (2018) Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol 31:480–490. https://doi.org/10.20524/aog.2018.0266

doi: 10.20524/aog.2018.0266

Shouval D, Shibolet O (2013) Immunosuppression and HBV reactivation. Semin Liver Dis 33:167–177. https://doi.org/10.1055/s-0033-1345722

doi: 10.1055/s-0033-1345722 pubmed: 23749673

Su YC, Lin PC, Yu HC, Wu CC (2018) Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy. Eur J Gastroenterol Hepatol 30:925–929. https://doi.org/10.1097/MEG.0000000000001130

doi: 10.1097/MEG.0000000000001130 pubmed: 29621049

Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E et al (2016) American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68:1–25. https://doi.org/10.1002/acr.22783

doi: 10.1002/acr.22783 pubmed: 26545825

Lok ASF, McMahon BJ et al (2004) Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD) Chronic hepatitis B: update of recommendations. Hepatology 39:857–861. https://doi.org/10.1002/hep.20110

doi: 10.1002/hep.20110 pubmed: 14999707

Sarin SK, Kumar M, Lau GK et al (2016) Asian-Pacific clinical practice guidelines on the management of hepatitis B. Hepatol Int 10:1–98. https://doi.org/10.1007/s12072-015-9675-4

doi: 10.1007/s12072-015-9675-4 pubmed: 26563120

Pawlowska M, Flisiak R, Gil L, Horban A, Hus I, Jaroszewicz J, Lech-Maranda E, Styczynski J (2019) Prophylaxis of hepatitis B virus (HBV) infection reactivation—recommendations of the Working Group for prevention of HBV reactivation. Clin Exp Hepatol 3:195–202. https://doi.org/10.5114/ceh.2019.87631

doi: 10.5114/ceh.2019.87631

Loomba R, Liang TJ (2017) Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 152:1297–1309. https://doi.org/10.1053/j.gastro.2017.02.009

doi: 10.1053/j.gastro.2017.02.009 pubmed: 28219691

Varley CD, Winthrop KL (2021) Long-term safety of rituximab (risks of viral and opportunistic infections). Curr Rheumatol Rep 23:74–84. https://doi.org/10.1007/s11926-021-01037-3

doi: 10.1007/s11926-021-01037-3 pubmed: 34269903 pmcid: 8284038

Onorato L, Pisaturo M, Camaioni C, Grimaldi P, Codella AV, Calo F, Coppola N (2021) Risk and prevention of hepatitis B virus reactivation during immunosuppression for non-oncological diseases. J Clin Med 10:5201. https://doi.org/10.3390/jcm10215201

doi: 10.3390/jcm10215201 pubmed: 34768721 pmcid: 8584565

Fidan S, Capkın E, Arıca D, Durak S, Okatan IE (2021) Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy. Int J Rheum Dis 24:254–259. https://doi.org/10.1111/1756-185X.14034

doi: 10.1111/1756-185X.14034 pubmed: 33244900

Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B et al (2012) Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases. Clin Rheumatol 31:931–936. https://doi.org/10.1007/s10067-012-1960-1

doi: 10.1007/s10067-012-1960-1 pubmed: 22349880

Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S (2004) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoidarthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62:686–687. https://doi.org/10.1136/ard.62.7.686

doi: 10.1136/ard.62.7.686

Lau G, Yu ML, Wong G, Thompson A et al (2021) APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hep Intl 15:1031–1048. https://doi.org/10.1007/s12072-021-10239-x)

doi: 10.1007/s12072-021-10239-x)

Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F et al (2011) Hepatitis B virus (HBV) reactivation in patients receiving tumornecrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90:359–371. https://doi.org/10.1097/MD.0b013e3182380a76

doi: 10.1097/MD.0b013e3182380a76 pubmed: 22033451

Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, VanVlierberghe H (2010) Subfulminant hepatitis B duringtreatment with adalimumab in a patient withrheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol 22:494–499. https://doi.org/10.1097/meg.0b013e3283329d13

doi: 10.1097/meg.0b013e3283329d13 pubmed: 20306568

Lucifora J, Xia Y, Reisinger F et al (2014) Specific and non hepatotoxic degradation of nuclear hepatitis Bvirus cccDNA. Science 343:1221–1228. https://doi.org/10.1126/science.1243462

doi: 10.1126/science.1243462 pubmed: 24557838 pmcid: 6309542

Pers YM, Jorgensen C (2016) Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases. Immunotherapy 8:1091–1096. https://doi.org/10.2217/imt-2016-0003

doi: 10.2217/imt-2016-0003 pubmed: 27485081